Literature DB >> 21618696

Transcriptome at the time of hepatitis C virus recurrence may predict the severity of fibrosis progression after liver transplantation.

Valeria Mas1, Daniel Maluf, Kellie J Archer, Amiee Potter, Jihee Suh, Ricardo Gehrau, Valeria Descalzi, Federico Villamil.   

Abstract

Allograft gene expression analysis may provide insights into the mechanisms involved in liver damage during hepatitis C virus recurrence (HCVrec) after orthotopic liver transplantation (OLT) and allow the identification of patients who have a higher risk of developing severe disease. Forty-three OLT recipients with hepatitis C virus (HCV) were evaluated. Genomewide gene expression analysis was performed with formalin-fixed, paraffin-embedded (FFPE) liver biopsy samples obtained from 21 OLT recipients with HCV at the time of clinical HCVrec, which was defined as increased alanine aminotransferase levels and detectable HCV RNA levels in serum. Patients were classified into 3 groups according to the severity of the fibrosis in the liver biopsies at 36 months post-OLT : group 1 (G1) for mild fibrosis (F0-F1), group 2 for moderate fibrosis (F2), and group 3 (G3) for severe fibrosis (F3-F4). No significant differences were observed between the groups with respect to donor age, histology during HCVrec, treated episodes of acute cellular rejection, or immunosuppression therapy. The results were validated in the remaining 22 OLT recipients with HCV using quantitative real-time polymerase chain reaction. Fifty-seven beadtypes showed significantly different expression (P < 0.001) between the groups during HCVrec. In G3, the gene expression of interleukin-28RA (IL-28RA), IL-28, and angiotensin-converting enzyme was up-regulated. Samples from G1 and G3 were used to determine whether a multigenetic classifier could be derived to predict the group class. The final model included the intercept and 9 bead types. Pairwise scatter plots of these 9 bead types revealed that G1 and G3 were well separated with respect to each gene. Our analysis has demonstrated the utility of a set of molecular markers indicating HCVrec severity early after OLT.
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21618696     DOI: 10.1002/lt.22309

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  3 in total

1.  Early transcriptional programming links progression to hepatitis C virus-induced severe liver disease in transplant patients.

Authors:  Angela L Rasmussen; Nicolas Tchitchek; Nathan J Susnow; Alexei L Krasnoselsky; Deborah L Diamond; Matthew M Yeh; Sean C Proll; Marcus J Korth; Kathie-Anne Walters; Sharon Lederer; Anne M Larson; Robert L Carithers; Arndt Benecke; Michael G Katze
Journal:  Hepatology       Date:  2012-06-05       Impact factor: 17.425

2.  Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update.

Authors:  Gamal Shiha; Alaa Ibrahim; Ahmed Helmy; Shiv Kumar Sarin; Masao Omata; Ashish Kumar; David Bernstien; Hitushi Maruyama; Vivek Saraswat; Yogesh Chawla; Saeed Hamid; Zaigham Abbas; Pierre Bedossa; Puja Sakhuja; Mamun Elmahatab; Seng Gee Lim; Laurentius Lesmana; Jose Sollano; Ji-Dong Jia; Bahaa Abbas; Ashraf Omar; Barjesh Sharma; Diana Payawal; Ahmed Abdallah; Abdelhamid Serwah; Abdelkhalek Hamed; Aly Elsayed; Amany AbdelMaqsod; Tarek Hassanein; Ahmed Ihab; Hamsik GHaziuan; Nizar Zein; Manoj Kumar
Journal:  Hepatol Int       Date:  2016-10-06       Impact factor: 6.047

3.  Biomarkers of disease differentiation: HCV recurrence versus acute cellular rejection.

Authors:  Ricardo Gehrau; Valeria Mas; Kellie Archer; Daniel Maluf
Journal:  Fibrogenesis Tissue Repair       Date:  2012-06-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.